Strong figures
With sales growth of 20%, rising sales prices and strategically effective acquisitions, Holcim opens the financial year with a strong first quarter. The building materials producer significantly exceeded analysts' consensus estimates, particularly in terms of EBIT. The Solutions & Products segment in particular is expected to continue to grow strongly; in 2022, the segment should account for at least 17% of Group sales, which would correspond to an increase of 3%.
Transformation holds potential
Holcim is not only strengthening its focus on Solutions & Products through acquisitions, but is also aiming to significantly reduce its dependence on the energy- and capital-intensive cement business. In addition, the share of the emerging markets business in the Group result is to be reduced, among other things through divestments.
Exit from India
This morning it was announced that the sale of the India business - a 63% stake in India's Ambuja Cements - to Adani Group has been signed, with proceeds from the sale amounting to CHF 6.4 billion. For Holcim, this will result in significantly lower net debt of less than CHF 4 billion (previously CHF 10 billion), enabling further growth steps in the Solutions & Products segment.
As planned, the sale in India reduces Holcim's dependence on the cement business in the emerging markets. Not to be neglected is also the reduction of the Group's environmental footprint, which goes hand in hand with this sale.
ZKB Equity Research rates the Holcim share as "overweight" and therefore assumes a relative overperformance.
Reverse Convertible on Holcim
indicative information
Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements.
The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document.
If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen.
ZKB Barrier Reverse Convertible mit bedingtem Coupon on worst of Salesforce.com Inc/NVIDIA Corp/Supe... 132913957 / CH1329139575 |
ZKB Autocallable Barrier Reverse Convertible on worst of Biogen Inc/BioNTech SE/Moderna Inc 132913422 / CH1329134220 |
ZKB Reverse Convertible auf Moderna Inc 135805537 / CH1358055379 |
22.09% ZKB Reverse Convertible, 16.01.2025 on worst of NVDA UW/TSLA UW/MRNA UW NVIDIA Corp/Tesla Inc... 130398418 / CH1303984186 |
11.17% ZKB Reverse Convertible, 03.03.2025 on worst of QCOM UW/AAL UW/MRNA UW Qualcomm Inc/American ... 135805027 / CH1358050271 |